Thermo Fisher Scientificreason 03 of 4it gets paid again without selling againderived 2026-09-11accession 0000097745-26-000144
On March 24, 2026, the company acquired Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials
The clinical research business grew $441 million in Q2 2026, contributing 7 percentage points of reported growth in the Laboratory Products and Biopharma Services segment, primarily driven by the impact of the Clario acquisition
The acquisition expands the segment's portfolio with the addition of highly complementary clinical research offerings, enabling customers to gain critical insights from clinical data to improve decision-making, accelerate innovation and drive greater productivity
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedfour sentences · whole, uncut
the claims it rests on
“On March 24, 2026, the company acquired Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials”
“The clinical research business grew $441 million in Q2 2026, contributing 7 percentage points of reported growth in the Laboratory Products and Biopharma Services segment, primarily driven by the impact of the Clario acquisition”
“The acquisition expands the segment's portfolio with the addition of highly complementary clinical research offerings, enabling customers to gain critical insights from clinical data to improve decision-making, accelerate innovation and drive greater productivity”
what it was checked against
Clario acquisition date and description
“On March 24, 2026, the company acquired, within the Laboratory Products and Biopharma Services segment, Clario Holdings, Inc., a U.S.-based leading provider of endpoint data solutions for clinical trials.”